This article is more than 5 years old. Information may no longer be current.

House dust mite SLIT-tablet advances to phase 3 clinical development

The investigational house dust mite sublingual immunotherapy tablet for the treatment of patients with allergic rhinitis with and without conjunctivitis has advanced to phase 3 clinical development in North America, according to a press release.

The house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet, MK-8237 (Merck/ALK-Abello), will be used in a trial of approximately 1,500 patients to investigate its safety and efficacy.

In 2013, two phase 3 clinical trials were completed in Europe, according to the release.